Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized trial of tralokinumab monotherapy in moderate-to-severe atopic dermatitis
2016-004200-65Phase 3Completed
- Sponsor
- LEO Pharma
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Tralokinumab with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint (initial treatment period). Started Jun 2017; status: completed.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2016-004200-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004200-65.